{"id":"regadenoson-peripheral-central","safety":{"commonSideEffects":[{"rate":null,"effect":"Flushing"},{"rate":null,"effect":"Dyspnea"},{"rate":null,"effect":"Chest discomfort"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Regadenoson selectively binds to adenosine A2A receptors on coronary vascular smooth muscle, triggering vasodilation and increasing coronary blood flow without the systemic effects of non-selective adenosine agonists. This allows assessment of myocardial perfusion during pharmacologic stress testing in patients unable to exercise. The peripheral-central designation likely refers to the route of administration or distribution characteristics in this phase 3 formulation.","oneSentence":"Regadenoson is an adenosine A2A receptor agonist that causes coronary vasodilation to increase blood flow, used for cardiac stress testing.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:31:46.225Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pharmacologic stress agent for myocardial perfusion imaging in patients unable to exercise"}]},"trialDetails":[{"nctId":"NCT01809743","phase":"PHASE3","title":"Regadenoson and Adenosine","status":"COMPLETED","sponsor":"Lokien van Nunen","startDate":"2013-01","conditions":"Coronary Artery Disease","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Regadenoson peripheral - central","genericName":"Regadenoson peripheral - central","companyName":"Lokien van Nunen","companyId":"lokien-van-nunen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Regadenoson is an adenosine A2A receptor agonist that causes coronary vasodilation to increase blood flow, used for cardiac stress testing. Used for Pharmacologic stress agent for myocardial perfusion imaging in patients unable to exercise.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}